Revenue for the fourth quarter and full year 2024 was $47.5 million and $179.0 million, respectively. The MRD business, which contributed 85% of revenue in the fourth quarter and 81% of revenue in the ...
Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating ...
A revolutionary approach to immune therapy has emerged: engineered immune cells that protect healthy tissue without ...
Understand RA from early to advanced stages. Explore symptoms, treatments, and lifestyle tips to manage rheumatoid arthritis ...
Having a 'moon face' can be a sign of Cushing syndrome, but that's typically not the only symptom. Here's what experts want ...
The human microbiome market share is expected to reach US$ 4.85 billion by 2031, driven by increased investments in research, ...
Göran Forsberg, CEO, steps downDamian Marron, Board Director, to assume role of Interim CEORecruitment process for new permanent CEO underway LUND, SWEDEN / ACCESS Newswire / February 5, 2025 / Cantar ...
Thermo Fisher Scientific Inc. announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Registry.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback